CAM 17.1--a new diagnostic marker in pancreatic cancer. by Gansauge, F. et al.
British Journal of Cancer (1996) 74, 1997-2002
© 1996 Stockton Press All rights reserved 0007-0920/96 $12.00
CAM 17.1-A new diagnostic marker in pancreatic cancer
F Gansaugel, S Gansauge', N Parker2, MI Beger', B Poch', KH Link', F Safi' and Hans G Beger'
'Department ofGeneral Surgery, University of Ulm, Steinhoevelstr. 9, 89075 Ulm, Germany; 2Euro DPC, Glyn-Rhonwy, Llanberis
Gwynedd, North Wales, UK.
Summary CAM 17.1-Ab is a recently described monoclonal antibody that detects a mucus glycoprotein with
high specificity for intestinal mucus, particularly in the colon, small intestine, biliary tract and pancreas. We
investigated the expression and release of CAM 17.1 in pancreatic carcinoma cell lines and tissue specimens of
normal pancreas, chronic pancreatitis and pancreatic cancer. CAM 17.1 was weakly expressed on normal
ductal cells and chronic pancreatitis, whereas it was overexpressed in pancreatic cancer. Serum analysis using a
new enzyme-linked antibody sandwich assay (CAM 17.1/WGA) of patients with chronic pancreatitis,
pancreatic cancer or other gastrointestinal cancer and ofhealthy blood donors revealed a high sensitivity (67%)
and excellent specificity (90%) of CAM 17.1/WGA assay in pancreatic cancer. In comparison with the tumour
marker CA19-9, the sensitivity of the CAM 17.1/WGA assay was similar to the sensitivity of CA 19-9 (67%
and 76%, P=0.22), whereas the specificity of CAM 17.1/WGA assay was higher than in CA 19-9 (90%
compared with 78% in chronic pancreatitis, P>0.05).
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Mucus-producing cells are very characteristic of epithelial
tissues. Mucus covers the surface of most epithelia and plays
a fundamental role in the lubrication and protection of
mucosal surfaces (Neutra and Forstner, 1987). Mucus is
biochemically complex and heterogeneous, its major compo-
nents being mucin glycoproteins (Neutra and Forstner, 1987;
Kaliner, 1991). Mucin glycoproteins are characterised by a
high carbohydrate content (greater than 80%) and core
peptides that are rich in Thr, Ser, Pro, Ala and Gly (Kaliner,
1991; Kim et al., 1991; Neutra and Forstner, 1987; Wesley et
al., 1985). As more than 90% of pancreatic cancers are
adenocarcinomas of ductal origin, these cancers frequently
contain mucin-producing cells as detected by histochemical
stains, whereas normal pancreatic tissue constitutes only a
minor portion of cells in the secretory ducts (Roberts and
Burns, 1972). The altered structure of mucins in pancreatic
carcinomas has been extensively documented at the
oligosaccharide level (Balague et al., 1994; Schiissler et al.,
1991; Takahashi et al., 1988; Xu et al., 1989). Mucins are also
often detectable in the serum of patients suffering from
pancreatic cancer; these include the blood group antigen
sialylated Lewisa, which is the epitope for the antibody
detecting CA19-9 (Magnani et al., 1983) and Thomsen-
Friedenreich antigen (galactose ,B1 -30-N-acetylgalactosa-
mine) (Ching and Rhodes, 1988, 1990), which is the epitope
for the lectin peanut agglutinin (PNA). Many reports have
evaluated the practicality of using tumour markers such as
CA19-9, CEA, CA50, CA242, CA494 and others for the
serological diagnosis of pancreatic cancer and the follow-up
of patients after tumour resection for pancreatic cancer
(Frebourg et al., 1988; Freiss et al., 1993; Habib et al., 1986;
Haglund et al., 1986; Kalser et al., 1978; Lucarotti et al.,
1991; Nilsson et al., 1992; Ohshio et al., 1990; Von Rosen et
al., 1993; Safi et al., 1986; Toshkov et al., 1994). In 1992,
Parker et al. firstly reported a new enzyme-linked antibody
sandwich assay (CAM 17.1/WGA) using the monoclonal
antibody CAM 17.1, which was generated after immunisation
with Coll 2-23 colorectal cancer cells. CAM 17.1 is an
immunoglobulin M antibody with high specificity for
intestinal mucus, particularly in the colon, small intestine,
biliary tract and pancreas (Makin et al., 1984; Raouf et al.,
1991). Erythrocyte agglutination studies revealed that the
epitope detected by the CAM 17.1 antibody is a sialysated
blood group antigen and is probably related to the I antigen,
which is absent from cord blood (Parker et al., 1992).
In the present study, we investigated the expression and
the release of CAM 17.1 in tissue specimens of normal
pancreas, chronic pancreatitis, pancreatic carcinoma and
pancreatic carcinoma cell lines using immunohistochemistry
and FACS analysis. The serum concentration of CAM 17.1
in patients with pancreatic cancer, chronic pancreatitis, non-
pancreatic cancer and in healthy blood donors was monitored
by ELISA.
Material and methods
Cell lines, culture conditions, tissues and sera
The human pancreatic tumour cell lines BxPC3, AsPC1,
Capan-1, Capan-2, Panc 1 and MIA PaCa 2 were obtained
from the American Type Culture Collection (ATCC),
Rockville, MD, USA. The pancreatic cell lines PMH 2/89
and PMH3/89 were grown from primary cultures of an
adenocarcinoma (Gansauge et al., 1994). All cell lines were
cultured in Dulbecco's modified eagle medium (DMEM)
purchased from Serva, Heidelberg, Germany. The medium
was supplemented with 10% fetal calf serum (FCS),
penicillin/streptomycin and glutamine (Biochrom, Berlin,
Germany). The cells were incubated at 37°C in 5% carbon
dioxide atmosphere. Each cell line was grown in 10 cm Petri
dishes to semiconfluent layers. For stimulation experiments,
cells were incubated with interferon-y (200 U ml-', R&D
Systems, Minneapolis, MN, USA), TNF-cx (1000 U ml-',
R&D Systems) and/or interleukin I1, (IL-If,) (10 U ml-1,
Amersham, Braunschweig, Germany). For subsequent FACS
analyses, the cells were removed from the dishes by
trypsination or in the case of protein lysate preparations by
mechanical scraping. Normal pancreatic tissue samples (n =8)
were obtained through an organ donor programme. Speci-
mens of pancreatic carcinoma (21 specimens of ductal
pancreatic adenocarcinoma; patient mean age 59 years,
range 39 -75 years, 12 women, 9 men) and chronic
pancreatitis (n = 19; patient mean age 51 years, range 26-
69 years, 8 women, 13 men) were obtained from patients
undergoing surgery at the Department of General Surgery at
the University of Ulm.
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Sera were obtained from a consecutive series of patients
seen at the Department of General Surgery between February
1994 and October 1995. Sera were collected at the time of
admission and stored at -70°C until ELISA was performed.
We studied sera from patients with pancreatic cancer (n=91:
ductal adenocarcinoma, n = 79; cystadenocarcinoma, n = 12),
chronic pancreatitis (n =93), colorectal cancer (n = 30), gastric
cancer (n=20) and from blood donors (n= 30). All cases of
carcinoma were confirmed histologically; TNM staging was
available in all but two cases.
Immunohistochemistry
Frozen sections were fixed in ice-cold methanol for 10 min,
washed in phosphate-buffered saline (PBS) and incubated
with normal goat serum (10% in PBS). After washing three
times in PBS, sections were incubated with the primary
antibody CAM 17.1-Ab for 1 h (purified antibody
(100 jug ml-'), diluted 1:100). After two washes with PBS,
sections were incubated for 30 min with peroxidase-
conjugated secondary antibody anti-mouse (DAKO, Santa
Barbara, CA, USA). For the negative control, a monoclonal
mouse antibody (IgM, Dako) was used in the same
concentration. Visualisation of the immunocomplexes was
performed with DAB (diaminobenzidine, Sigma, Taufkirch-
en, Germany). The cells were counterstained with haematox-
ylin, mounted with glycerol gelatin and then viewed by
microscopy. The negative control showed no background
staining.
Flow cytometric analysis
Following trypsination, cells were washed twice in PBS 1%
bovine serum albumin (BSA), resuspended and seeded into
microtitre plates at a final concentration of I05 cells per well.
In order to reduce non-specific binding, 10 pl of goat
immunoglobulin (3 mg ml-') was added to each well. After
one washing step, the cells were incubated with the
unconjugated monoclonal antibodies, at the same concentra-
tions as used for immunohistochemistry, for 30 min on ice,
washed twice with 200 ,ul of PBS- 1% BSA and stained with
FITC-F(ab')2 fragment-conjugated goat anti-mouse IgM
(Dianova) for an additional 20 min. Following two washes
with PBS- 1% BSA, cells were fixed with 1% paraformalde-
hyde. For the negative control, the same antibody as
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described in immunohistochemistry was used. Fluorescence
analyses were performed with a FACScan flow cytometer
(Becton Dickinson).
CA19-9 and CEA determination
CA19-9 was measured with a commercial, solid-phase, two-
site immunoradiometric assay (EIA CIA19-9, CIS, Dreieich,
Germany). As described in other studies, 37 U ml-' was
considered the upper normal limit of the CA 19-9 assay (Safi
et al., 1986). The concentration of CEA was also determined
using a commercial, solid-phase, two-site enzyme immunoas-
say (EIA, Dreieich, Germany). In our study, the upper
normal limit of CEA was considered to be 3.0 ng ml-'
(O'Dwyer et al., 1988).
Wheat germ agglutinin (CAM 17.J/WGA) enzyme-linked
assay
The characteristics of the monoclonal antibody CAM 17.1-
Ab and the CAM 17.1/WGA assay have already been
described. The CAM 17.1/WGA assay was performed as
described before (Parker et al., 1992). The cut-off value was
considered to be at 37 AU 1-l as described before (Parker et
al., 1992).
Statistical analysis
The chi-square test or the Fisher's exact probability test was
used to analyse differences in the sensitivity or specificity of
the assays. The relationship between CA19-9 and CAM 17.1
serum levels in patients with pancreatic cancer was
determined by linear regression analysis. Differences in
Kaplan-Meier regression analysis were calculated by the
log-rank test. Significance was defined as P<0.05.
Results
Expression and shedding ofCAM 17.1 in pancreatic carcinoma
cell lines
In FACS analyses CAM 17.1 was expressed on all eight
tested cell lines (Figure 1). Determination of protein lysates
from the cell lines revealed a concentration of 0.76 AU 10-7
cells (range 0.16-1.58 AU 10-7 cells). The release of CAM
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Figure 1 FACS-analysis of CAM 17.1 expression on pancreatic carcinoma cell lines. All cell lines tested showed an expression of
CAM 17.1 (solid graph) compared with the negative control (outlined graph).
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Figure 2 Immunohistochemistry of pancreatic tissue specimens using CAM 17.1-Ab. In normal pancreatic tissue and chronic
pancreatitis only the ductal cells showed a weak expression of CAM 17.1 (a and b), whereas pancreatic carcinoma tissue and
pancreatic carcinoma cell lines showed an overexpression of CAM 17.1 (c and d).
Table I Positive results of CA 19-9, CEA and CAM 17.1 in patients with pancreatic cancer,
colorectal cancer, gastric cancer, chronic pancreatitis and in blood donors
CA 19-9 CEA CAM 17.1
(>37Uml) (>3ngnil) (>37 AU I-)
Pancreatic cancer 68/89 (76%) 45/89 (51%) 61/91 (67%)
Adenocarcinoma 57/77 (74%) 38/77 (49%) 50/79 (63%)
Cystadenocarcinoma 11/12 (92%) 7/12 (58%) 11/12 (92%)
Colorectal cancer 12/30 (39%) 17/30 (55%) 2/30 (7%)
Gastric cancer 9/20 (45%) 7/20 (35%) 4/20 (20%)
Chronic pancreatitis 20/93 (22%) 25/93 (27%) 9/93 (10%)
Blood donors 1/30 (3%) 0/30 (0%) 0/30 (0%)
17.1 into the supernatant was monitored by incubation of
5 x 106 cells for a time period of 24 h. CAM 17.1
concentrations in the cultured supernatant were determined
at 0 h, 12 h and 24 h. CAM 17.1 release rates varied between
2 and 21 AU 10-7 cells 24 h-' with a mean of 10.1 AU 10-7
cells 24 h-' indicating that sufficient amounts of CAM 17.1
were released into the culture medium by the pancreatic
carcinoma cell lines tested. Neither the release nor the cellular
concentration of CAM 17.1 was significantly affected by
stimulation with TNF-a, interferon-, or IL-1,B (data not
shown).
Expression of CAM 17.1 in nornmal pancreas, chronic
pancreatitis and pancreatic carcinoma
Immunohistochemical examination of pancreatic tissue
specimens showed a weak staining of CAM 17.1 on ductal
cells in normal pancreatic tissue (Figure 2), whereas 16/21
(76%) of the pancreatic adenoma sections showed a strong
immunoreactivity with CAM 17.1-Ab (Figure 2). Serum
analyses of these 21 cases revealed a close correlation
between tissue overexpression and elevated serum levels of
CAM 17.1. All specimens of chronic pancreatitis did not
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Figure 3 CAM 17.1 serum values (AU 1-) in patients with
pancreatic adenocarcinoma (n=79), chronic pancreatitis (n=93),
non-pancreatic cancer (n= 50) and in healthy blood donors
(n =30). The solid line represents the cut-off of CAM 17.1
(37AU I-').
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overexpress CAM 17.1 as compared with normal pancreas.
CAM 17.1 showed only a weak staining on ductal cells
(Figure 2).
Sensitivity and specificity of CAM 17.1
In patients with pancreatic cancer the sensitivity of CAM
17.1 was 67% (Table I, Figure 3). In adenocarcinoma and
cystadenocarcinoma, the sensitivity was 63% and 92%
respectively. The serum CAM 17.1 levels seemed to be
dependent on the tumour stage: the more advanced the
disease, the higher the serum CAM 17.1 levels (Figure 4).
In healthy blood donors and patients with chronic
pancreatitis, CAM 17.1 exceeded the cut-off level in 7.3%
(9/123). The specificity of CAM 17.1 in healthy volunteers,
patients with chronic pancreatitis, colorectal cancer patients
and gastric cancer patients was 100% (0/30), 90% (84/93),
93% (28/30) and 80% (16/20) respectively (Table I and
Figure 3).
CAM 17.1 serum levels in patients with pancreatic cancer
were not affected by the tumour differentiation and the
presence or absence of clinical jaundice. No correlation was
found between bilirubin levels and CAM 17.1, as well as CA
19-9, levels (Spearman's rank correlation test). The
sensitivity increased with increasing tumour stage (Table
II). Interestingly, there was a significant difference between
resectability and elevated CAM 17.1 levels; in the group of
patients with unresectable pancreatic adenocarcinomas the
sensitivity of CAM 17.1 was 78%, whereas only 49% of the
resectable patients showed elevated CAM 17.1 serum levels
(Table II).
Comparison of CAM 17.1 with CA 19-9 and CEA
The sensitivities of CAM 17.1 and CA 19-9 in detecting
pancreatic cancer were 67% and 76% respectively (P=0.22,
not significant). In these patients, both markers showed a
significant positive correlation (r =0.91, P>0.001) (Figure 5).
CEA was elevated in only 51% (Table I). Neither CAM 17.1
nor CA 19-9 serum levels were influenced by jaundice. CA
19-9 was dependent on tumour differentiation and CAM 17.1
was significantly more frequently positive in advanced
diseases and unresectable cases. There was a tendency for
median survival times in CAM 17.1- or CA 19-9-negative
patients to be higher than in positive cases (Table II).
Comparison of CAM 17.1 and CA 19-9 using receiver
operating characteristic curve analysis (ROC) revealed no
statistically significant difference between these two tumour
markers.
The specificity of CAM 17.1 for pancreatic cancer
in patients with colorectal or gastric cancer was significantly
higher than the specificity of CA 19-9 (CAM 17.1, 88%; CA
19-9, 58%; P>0.001). Also, in patients with chronic
pancreatitis, the most important control group for
pancreatic cancer, the specificity of CAM 17.1 was
significantly higher than the specificity of CA 19-9 (90%
and 78%; P>0.05). The combined evaluation of CAM 17.1
and CA 19-9 in patients with pancreatic cancer or chronic
10 000
1000
100
10
1
| CAM 17.1
| CA 19.9
I. 11 1III IV
(n = 15) (n = 6) (n = 34) (n = 24)
Tumour stage
Figure 4 CA 19-9 (Uml-1) and CAM 17.1 (AUI') and
dependence on tumour stage in 79 patients with pancreatic
adenocarcinoma. Values are medians with upper and lower
quartiles. C], CAM 17.1; *, CA 19.9.
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Figure 5 Correlation of CA 19-9 (Uml-) and CAM 17.1
(AUI-1) in 79 patients with pancreatic adenocarcinoma.
Correlation coefficient r=0.91, P>0.001. The horizontal line
represents the cut-off value of CAM 17.1(37AU -1); the vertical
line is the cut-off of CA 19-9 (37Uml-).
Table II Positive results of CAM 17.1 and CA 19-9 in regard to tumour stage, grading, jaundice, resectability and survival
CAM 17.1 CA 19-9
Positive (%) Negative (%) P-value Positive (%) Negative (%) P-value
Staging
Stage I and II 48 52 67 33
Stage III 59 41 I+II vs IV 74 26 I+II vs IV
Stage IV 79 21 >0.02 82 18 0.2
Grading
Well and moderately differentiated 54 46 63 37
Undifferentiated 59 41 0.43 86 14 > 0.05
Icterus
Jaundiced 60 40 77 23
Non-jaundiced 54 46 0.4 65 35 0.2
Resectability
Resectable 49 51 69 31
Unresectable 78 22 >0.02 77 23 0.35
Median survival
(months) 8.5 13.3 0.2 8.9 12.5 0.1
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pancreatitis revealed a sensitivity of 64% and a specificity of
94% under the condition that both tumour markers were
positive.
Discussion
The early diagnosis of pancreatic cancer is fundamental to
the improvement of its poor prognosis. Although the
sensitivity and specificity of imaging techniques such as
ultrasonography, enhanced computerised tomography and
endoscopic retrograde cholangiopancreaticography (ERCP)
has increased, these techniques do not offer screening
facilities because of their expense and their potential for
complications (Warshaw and Fernandez-Del, 1992). There-
fore, non-invasive, simple and reliable tests are necessary for
diagnosis and follow-up of patients with cancer. Many
tumour markers for the diagnosis of pancreatic cancer, such
as galactosyltransferase II (Podolsky et al., 1981), leucocyte-
adherence inhibition assay (Russo et al., 1978), pancreatic
oncofetal antigen (Gelder et al., 1978) and serum ribonu-
clease (Warshaw et al., 1980), have been intensively
investigated for their potential use but were not introduced
into clinical practice, mainly because of their limited
sensitivity and specificity or the impracticability of the test
system. So far, the golden standard with which every new
serum marker for pancreatic cancer should be compared is
CA 19-9. This tumour marker has been shown to have an
excellent sensitivity (71 -89%) for adenocarcinoma of the
pancreas and a high specificity in pancreatic cancer diseases
(Frebourg et al., 1988; Haglund et al., 1986; Lucarotti et al.,
1991; Magnani et al., 1983; Ohshio et al., 1990; Von Rossen
et al., 1993; Safi et al., 1986; Toshkov et al., 1994). The
monoclonal antibody CAM 17.1 detects a mucus glycopro-
tein with a high specificity for intestinal mucus, particularly
in the colon, small intestine, biliary tract and pancreas
(Makin et al., 1984; Raouf et al., 1991). Immunohistological
analysis of pancreatic tissue specimens revealed an over-
expression of the CAM 17.1 antigen in pancreatic cancer. In
pancreatic carcinoma cell lines, we observed a high expression
of CAM 17.1. Taken together with high CAM 17.1 levels in
the culture supernatants, we were able to demonstrate a high
turnover rate of CAM 17.1 in these cell lines. These in vitro
data correspond well with the observation that CAM 17.1
serum levels increase with increasing tumour stages and
resectability, suggesting that in CAM 17.1-positive cases, the
serum levels reflect the amount of tumour cells burden. In
comparison with CA 19-9, CAM 17.1 had a similar
sensitivity and a higher specificity, especially in patients
with chronic pancreatitis. This could offer a better
opportunity to distinguish benign from malignant pancreatic
tumours because in clinical practice it is often difficult to
distinguish patients with chronic pancreatitis combined with
an inflammatory enlargement of the pancreatic head from
patients with malignant pancreatic tumours.
CEA, the oldest commercially available and widely used
serum tumour marker, has a low rate of accuracy in detecting
patients with pancreatic cancer and in ruling out patients
suffering from non-malignant pancreatic diseases. Therefore,
it is not reliable for monitoring pancreatic cancer, whereas in
carcinomas of the colon its value is undisputed (Northover,
1986).
In conclusion, we have described the cellular expression and
the release of a new tumour-associated antigen which is
detected by the monoclonal antibody CAM 17.1. We further
investigated the potential use of this tumour marker in
pancreatic cancer, and in comparison to CA 19-9 we found a
significantly higher specificity and a similar sensitivity ofCAM
17.1. These data suggest that CAM 17.1, besides having a
similar sensitivity to CA 19-9, provides additional information
for use in the differentiation between chronic pancreatitis and
pancreatic carcinoma. Further studies in larger series of
patients will be carried out to confirm the data presented.
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